Quantcast
 
Read Larry Connors' blogShort Term Trading Strategies



Where the economy and markets might be heading

By Peter Navarro | TradingMarkets.com
Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Navarro’s Big Economic Picture: (Bill) Gross’ed Out

I’d like to reflect this week on a couple of stories that caught my eye the last week or so -- each of which gives us a different, but interesting, take on where the economy and markets might be heading. As a reference point, let’s start with the observation that the brief August rally we had bit the dust last week -- and likely was more of a short squeeze rally as opined in last week’s missive. Now for the stories:

The first story appeared in the Wall Street Journal and pretty much wrote the obituary on Bill Gross as a credible prognosticator. Gross is, of course, Pimco’s bond king and oft-quoted market pundit. Seems like its been almost four years now that Gross has been getting the markets’ direction wrong, he’s not sleeping at night or eating well, and, most importantly, his investors have been taking a pretty good haircut.

I can see how Gross has gotten into so much trouble. For several years now, the bad economic news has been mounting; and a reasonable speculator like Gross could easily jump to the conclusion that the bear is nigh. His own problems started in September of 2002 when he projected a value of 4,000 for the Dow. That was pretty radical at the time; and anybody who had jumped on that advice on the short side, would have lost his shirt. The question is how an ultra-brain like Gross can get everything so wrong -- particularly the bond market which he has hitherto owned.

One answer appears in the second story that caught my eye. Seems like most of the profits that U.S. corporations are raking in these days are going to stock buybacks. There’s no more efficient way to keep stock prices propped up than that -- particularly since the flood of money is now more than offsetting all the new stock options these companies are awarding.

The third story of interest has to do with how consumers are -- finally! -- responding to higher gas prices, higher rates on their adjustable rate mortgages, and the declining use of home refinancing to serve as an ATM. Consumers are cutting back -- oh duh -- on at least some of their consumer spending -- and the retailing sector is taking a hit. That story confirms the insight that oil price shocks and rate hikes are contractionary -- but again, Gross’s timing has been wrong. Call in premature Bearitis.

I think that Gross is eventually going to be right about the stock market bear -- a sustained oil price shock, a long-term budget deficit, a non-coincidentally weakening dollar bringing inflation, the loss of U.S. manufacturing jobs and declining per capita income, and a thousand other unkind economic cuts are taking their toll on Goliath. Still, yet a fourth story that caught my eye made me start thinking about domestic stock markets -- whether in Germany, the U.S. or elsewhere -- in a different way.

This story focused on how the German stock market was outperforming the domestic economy by leaps and bounds. The reason: a lot of German companies are conducting operations -- both production and sales and distribution -- outside the Fatherland. So even as Germans cry in their beer over a stagnant economy and high unemployment, the shareholders in German companies -- from Riyadh to Toronto -- are toasting their good fortune.

The broader point here -- and I think it may be at least semi-profound -- is that we can no longer view domestic stock markets as leading indicators of domestic economies. Instead, we as forecasters must look at the whole web of exchanges around the world and parse their effects region by region and country by country. This is a whole lot harder than it used to be -- which is why folks like Gross uncharacteristically have been losing their way.

This Week’s Market Movers -- Visions of GDP Revisions

While a lot of big players will be heading for the beaches this week, there will be some interesting reports vying for investor attention. We get a double dose of consumer confidence -- The Conference Board’s on Monday and U-Mich’s on Friday. Both should signal a gloomier consumer -- so any upside surprise would be bullish. My big market mover of the week bet is on the revision to 2nd quarter GDP. There’s talk that it will be ratcheted up to over 3%, which would be bearish as it signals more inflation than previously thought.

Portfolio Shorts and Longs

Let’s start with my poodle (i.e., small dog) of the summer -- the Brazilian exchange-traded fund (EWZ | Quote | Chart | News | PowerRating). I bought in at $40ish, scale in a bit more at $41ish and last week lost a couple of points in a Brazilian downdraft and cut my losses quick. Licking my wounds, I sought answers. Here’s two: First, the Brazilian economy has been lifted on a sea of commodity price hikes -- from soybeans to metals -- and those markets may be softening. Second, Brazilian elections are soon and the Socialist leader Lulu, who looked to be in big trouble just months ago, is now pulling away with the race -- putting Brazilian entrepreneurs in a deep funk.

Now let’s turn to (EPIXD | Quote | Chart | News | PowerRating). This was my hot August stock -- right out of Vaino’s biotech corner. Well, last week, the technicals turned South. I promptly cut my position by 75% and took some nice gains off the table. If the stock breaks through the $7 support level, I will take the rest of it off the table -- but keep it high on my watch list for a reload.

Meanwhile, I’m sitting tight on three biotechs -- (ABAX | Quote | Chart | News | PowerRating), (AXCA | Quote | Chart | News | PowerRating), and (HTI | Quote | Chart | News | PowerRating). Plus, my big buys of the week were two of my favorite stem cell plays -- (ASTM | Quote | Chart | News | PowerRating) and (STEM | Quote | Chart | News | PowerRating). Both seem stable at the low end of their ranges so downside risk is minimal. With the Republicans getting beat up on their opposition to stem cell research, the political tide should soon turn. And there has been some nice good news on the science front. These are, however, long term plays.

Peter Navarro is a business professor at the University of California and the author of the best-selling investment book “If It’s Raining in Brazil, Buy Starbucks” and the business shelf bestseller The Well-Timed Strategy.” His latest book is “The Coming China Wars.”


>> See more articles by Peter Navarro
Stocks RSS Bookmark and Share
Related Articles
More Related Articles >>
PREMIER SPONSORED LINKS
TRADE CENTER
 
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.